A
Andrew N. Antoszyk
Researcher at Uniformed Services University of the Health Sciences
Publications - 69
Citations - 7211
Andrew N. Antoszyk is an academic researcher from Uniformed Services University of the Health Sciences. The author has contributed to research in topics: Visual acuity & Ranibizumab. The author has an hindex of 32, co-authored 63 publications receiving 5810 citations. Previous affiliations of Andrew N. Antoszyk include Duke University.
Papers
More filters
Journal ArticleDOI
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
John A. Wells,Adam R. Glassman,Allison R. Ayala,Lee M. Jampol,Lloyd Paul Aiello,Andrew N. Antoszyk,Bambi Arnold-Bush,Carl W. Baker,Neil M. Bressler,David J. Browning,Michael J. Elman,Frederick L. Ferris,Scott M. Friedman,Michele Melia,Dante J. Pieramici,Jennifer K. Sun,Roy W. Beck +16 more
TL;DR: Intravitreous aflibercept, bevacizumAB, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity.
Journal ArticleDOI
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
Emily Y. Chew,Traci E Clemons,John Paul SanGiovanni,Ronald P. Danis,Frederick L. Ferris,Michael J. Elman,Andrew N. Antoszyk,Alan J. Ruby,David H. Orth,Susan B. Bressler,Gary E. Fish,Baker Hubbard,Michael L. Klein,Suresh R. Chandra,Barbara A Blodi,Amitha Domalpally,Thomas R. Friberg,Wai T. Wong,Philip J. Rosenfeld,Elvira Agrón,Cynthia A. Toth,Paul S. Bernstein,Robert Sperdut +22 more
TL;DR: Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not reduce risk of progression to advanced AMD, but because of potential increased incidence of lung cancer in former smokers, luteIn + zexanthin could be an appropriate carotenoid substitute in the ARedS formulation.
Journal ArticleDOI
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Jeffrey G. Gross,Adam R. Glassman,Lee M. Jampol,Seidu Inusah,Lloyd Paul Aiello,Andrew N. Antoszyk,Carl W. Baker,Brian B. Berger,Neil M. Bressler,David J. Browning,Michael J. Elman,Frederick L. Ferris,Scott M. Friedman,Dennis M. Marcus,Michele Melia,Cynthia R. Stockdale,Jennifer K. Sun,Roy W. Beck +17 more
TL;DR: Treatment with ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years, and may be a reasonable treatment alternative, at least through 1 years, for patients with proliferative diabetic retinopathy.
Journal ArticleDOI
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Jeffrey S. Heier,Andrew N. Antoszyk,Peter R. Pavan,Steven R. Leff,Philip J. Rosenfeld,Thomas A. Ciulla,Richard F. Dreyer,Ronald C. Gentile,Judy P. Sy,Gary Hantsbarger,Naveed Shams +10 more
TL;DR: Repeated intravitreal injections of ranibizumab had a good safety profile and were associated with improved VA and decreased leakage from choroidal neovascularization in subjects with neov vascular AMD.
Journal ArticleDOI
Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
David S. Boyer,Andrew N. Antoszyk,Carl C. Awh,Robert B. Bhisitkul,Howard Shapiro,Nisha R. Acharya,Nisha R. Acharya +6 more
TL;DR: This subgroup analysis of 24-month data from the MARINA study indicates that ranibizumab treatment was associated with an average increase from baseline VA in all subgroups evaluated, and that ranihazard treatment was superior to sham treatment across all sub groups.